DEALS: Quest acquisition broadens market share


Quest acquisition broadens market share


DEALS

WHO

WITH

WHAT

SCOOP

Quest Diagnostics

LabOne

$934M buyout

The deal expands Quest's penetration of the market for health screening and risk assessment services.

Meda

Viatris

€750M acquisition

The deal creates a big player in the European specialty pharma field.

Nektar Therapeutics

Aerogen

$32M buyout

The acquisition broadens Nektar's pulmonary delivery capabilities by adding advanced inhaleable liquid drug technology to Nektar's base.

GeoPharma

Consolidated Pharmaceutical

Asset acquisition

GeoPharma gains a controlling interest in an antibiotic manufacturing facility.

Pfizer

Bioren

Acquisition

The acquisition of Bioren strengthens Pfizer's commitment to the antibody space.

Paladin Labs

Dimethaid Health Care

Acquisition

Paladin gains control of Pennsaid, a lotion approved by Health Canada for the treatment of symptoms of knee osteoarthritis.

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.